We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
HUTCHMED
Data at EHA 2024 heighten focus on sovleplenibScancell
GlyMab evaluation agreement with major biotech playerANGLE
Scaling the business to drive continued momentumAvacta
Data and clinical progress validate pre|CISION platformArecor Therapeutics
AT278 ultra-concentrated insulin superior to benchmarksArecor Therapeutics
FY23 results evidence broader revenue baseANGLE
Gathering momentum in Pharma ServicesHUTCHMED
Strong US Fruzaqla Q1; EU approval could come soonArecor Therapeutics
Novel diabetes drug-device deal inked with MedtronicAvacta
Therapeutics focus sharpening; cash to key catalysts